Qiagen N.V. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Qiagen N.V. with three other
pharmaceutical manufacturers in Europe:
Vifor Pharma AG
sales of 1.34 billion Swiss Francs [US$1.39 billion]
of which 100%
(1.29 billion Euro [US$1.51 billion]
of which 84%
was Pharmaceuticals), and
Krka DD Novo Mesto
based in Slovenia
(1.27 billion Euro [US$1.49 billion]
of which 61%
was European Union).
Qiagen N.V. reported sales of 1.24 billion Euro (US$1.46 billion)
December of 2017.
increase of 2.7%
versus 2016, when the company's sales were 1.21 billion Euro.
Sales at Qiagen N.V. have increased during each of the previous five years
(and since 2012, sales have increased a total of 28%).
Sales of Consumables and Related Revenues saw an increase
3.3% in 2017, from
1.06 billion Euro to 1.09 billion Euro.
Not all segments of Qiagen N.V. experienced an increase in sales in 2017:
sales of Instrumentation fell 1.4% to 153.47 million Euro.